J&J Suspends Sales Forecast for COVID Vaccine Citing Uncertainty in Demand, Global Supply Surplus

Vials of the Johnson & Johnson COVID-19 vaccine are seen at a pharmacy in Denver, Colo., in a file photograph. David Zalubowski/AP Photo

Johnson & Johnson suspended sales forecasts for its COVID-19 vaccine on April 19, citing a global supply surplus and uncertainty when it comes to future demand for the shot.

The company had previously predicted as much as $3.5 billion in 2022 sales from the single-dose vaccine, but demand for the shot has dwindled behind that of the Moderna and Pfizer vaccines.